A detailed history of Van Eck Associates Corp transactions in Incyte Corp stock. As of the latest transaction made, Van Eck Associates Corp holds 134,881 shares of INCY stock, worth $9.29 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
134,881
Previous 161,993 16.74%
Holding current value
$9.29 Million
Previous $9.82 Million 10.49%
% of portfolio
0.01%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

SELL
$57.33 - $68.61 $1.55 Million - $1.86 Million
-27,112 Reduced 16.74%
134,881 $8.79 Million
Q2 2024

Jul 31, 2024

BUY
$51.18 - $63.75 $256,974 - $320,088
5,021 Added 3.2%
161,993 $9.82 Million
Q1 2024

Apr 30, 2024

BUY
$56.55 - $66.59 $24,429 - $28,766
432 Added 0.28%
156,972 $8.94 Million
Q4 2023

Feb 05, 2024

SELL
$52.16 - $64.19 $1.98 Million - $2.44 Million
-37,941 Reduced 19.51%
156,540 $9.83 Million
Q3 2023

Nov 08, 2023

BUY
$57.77 - $65.93 $700,345 - $799,269
12,123 Added 6.65%
194,481 $11.2 Million
Q2 2023

Aug 03, 2023

BUY
$60.95 - $75.51 $425,552 - $527,210
6,982 Added 3.98%
182,358 $11.4 Million
Q1 2023

May 03, 2023

SELL
$70.23 - $86.01 $2.74 Million - $3.36 Million
-39,039 Reduced 18.21%
175,376 $12.7 Million
Q4 2022

Feb 08, 2023

BUY
$67.18 - $84.11 $2.91 Million - $3.64 Million
43,245 Added 25.26%
214,415 $17.2 Million
Q3 2022

Oct 27, 2022

SELL
$66.18 - $82.86 $3.73 Million - $4.67 Million
-56,324 Reduced 24.76%
171,170 $11.4 Million
Q2 2022

Aug 03, 2022

BUY
$66.18 - $83.18 $2.38 Million - $2.99 Million
35,933 Added 18.76%
227,494 $17.3 Million
Q1 2022

May 10, 2022

BUY
$66.02 - $79.71 $2.66 Million - $3.22 Million
40,360 Added 26.69%
191,561 $15.2 Million
Q4 2021

Jan 26, 2022

SELL
$63.34 - $74.11 $1.11 Million - $1.29 Million
-17,464 Reduced 10.35%
151,201 $11.1 Million
Q3 2021

Nov 03, 2021

SELL
$68.67 - $84.02 $2.16 Million - $2.64 Million
-31,467 Reduced 15.72%
168,665 $11.6 Million
Q2 2021

Aug 10, 2021

BUY
$79.87 - $87.53 $619,152 - $678,532
7,752 Added 4.03%
200,132 $16.8 Million
Q1 2021

May 13, 2021

SELL
$76.02 - $100.5 $1.11 Million - $1.47 Million
-14,596 Reduced 7.05%
192,380 $15.6 Million
Q4 2020

Feb 09, 2021

BUY
$80.74 - $97.7 $795,208 - $962,247
9,849 Added 5.0%
206,976 $18 Million
Q3 2020

Nov 12, 2020

SELL
$85.07 - $109.69 $3.26 Million - $4.2 Million
-38,287 Reduced 16.26%
197,127 $17.7 Million
Q2 2020

Aug 10, 2020

BUY
$74.18 - $108.93 $3.3 Million - $4.84 Million
44,439 Added 23.27%
235,414 $24.5 Million
Q1 2020

May 12, 2020

BUY
$63.18 - $85.97 $1.33 Million - $1.81 Million
20,996 Added 12.35%
190,975 $14 Million
Q4 2019

Feb 13, 2020

SELL
$73.04 - $95.72 $1.41 Million - $1.85 Million
-19,293 Reduced 10.19%
169,979 $14.8 Million
Q3 2019

Nov 08, 2019

SELL
$72.82 - $86.52 $1.4 Million - $1.66 Million
-19,183 Reduced 9.2%
189,272 $14.1 Million
Q2 2019

Aug 07, 2019

SELL
$73.52 - $88.7 $752,036 - $907,312
-10,229 Reduced 4.68%
208,455 $17.7 Million
Q1 2019

May 13, 2019

SELL
$63.56 - $88.17 $3.05 Million - $4.23 Million
-47,968 Reduced 17.99%
218,684 $18.8 Million
Q4 2018

Feb 12, 2019

SELL
$58.5 - $69.94 $459,517 - $549,378
-7,855 Reduced 2.86%
266,652 $17 Million
Q3 2018

Nov 13, 2018

BUY
$61.75 - $74.23 $442,685 - $532,154
7,169 Added 2.68%
274,507 $19 Million
Q2 2018

Aug 13, 2018

BUY
$60.85 - $83.98 $2.73 Million - $3.77 Million
44,910 Added 20.19%
267,338 $17.9 Million
Q1 2018

May 11, 2018

SELL
$83.06 - $100.98 $4.67 Million - $5.67 Million
-56,189 Reduced 20.17%
222,428 $18.5 Million
Q4 2017

Feb 12, 2018

BUY
$93.56 - $116.6 $3.64 Million - $4.54 Million
38,902 Added 16.23%
278,617 $26.4 Million
Q3 2017

Nov 09, 2017

SELL
$109.15 - $138.27 $415,643 - $526,532
-3,808 Reduced 1.56%
239,715 $28 Million
Q2 2017

Aug 11, 2017

BUY
N/A
243,523
243,523 $30.7 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.3B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Van Eck Associates Corp Portfolio

Follow Van Eck Associates Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

News

Stay updated on Van Eck Associates Corp with notifications on news.